|1||NCT01690065||Recruiting||Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML||
||46||All||18 Years to 65 Years (Adult)||NCT01690065||CAMN107AKR07T||NICE-BORA||September 2012||September 2019||December 2019||September 21, 2012||May 11, 2016||
|2||NCT00471497||Active, not recruiting
|A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)||
||852||All||18 Years and older (Adult, Senior)||NCT00471497||CAMN107A2303
|ENESTnd||July 31, 2007||September 2, 2009||October 15, 2018||May 10, 2007||December 5, 2017||June 17, 2013||
† Study has passed its completion date and status has not been verified in more than two years.